Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
N/A1 (25.0%)

Trials by Status

completed125%
terminated375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00828009
terminatedphase_3

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
terminatedphase_3

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

NCT01015443
terminatednot_applicable

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

NCT01423760

Clinical Trials (4)

Showing 4 of 4 trials
NCT00828009Phase 2

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Completed
NCT02049151Phase 3

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

Terminated
NCT01015443Phase 3

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

Terminated
NCT01423760Not Applicable

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Terminated

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4